nortriptyline has been researched along with Depression, Involutional in 144 studies
Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.
nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.
Depression, Involutional: Form of depression in those MIDDLE AGE with feelings of ANXIETY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Suicidal ideation is a frequent and difficult-to-treat clinical challenge among patients with major depressive disorder (MDD)." | 6.90 | Trajectories of Suicidal Ideation During 12 Weeks of Escitalopram or Nortriptyline Antidepressant Treatment Among 811 Patients With Major Depressive Disorder. ( Aitchison, KJ; Behrendt-Møller, I; Buttenschøn, HN; Dernovsek, MZ; Hauser, J; Henigsberg, N; Köhler-Forsberg, O; Madsen, T; Maier, W; McGuffin, P; Mors, O; Perroud, N; Rietschel, M; Souery, D; Uher, R, 2019) |
| " A sustained remission rate of 50% over 2 years in patients with severe major depression who were treated with nortriptyline monotherapy after successful ECT is encouraging." | 5.69 | Clinical characteristics associated with relapse 2 years after electroconvulsive therapy for major depression. ( Birkenhäger, TK; Kamperman, AM; Pluijms, EM; Vinther, PT, 2023) |
| " The authors tested the hypothesis that C-reactive protein (CRP), a commonly available marker of systemic inflammation, predicts differential response to escitalopram (a serotonin reuptake inhibitor) and nortriptyline (a norepinephrine reuptake inhibitor)." | 5.19 | An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. ( Dernovsek, MZ; Dew, T; Farmer, A; Hauser, J; Henigsberg, N; Maier, W; McGuffin, P; Mors, O; Souery, D; Tansey, KE; Uher, R, 2014) |
| "In genome-based drugs for depression (GENDEP), 811 patients with major depressive disorder treated with escitalopram or nortriptyline were assessed with the clinician-rated Montgomery-Åsberg Depression Rating Scale (MADRS), Hamilton Rating Scale for Depression (HRSD), and the self-report Beck Depression Inventory (BDI)." | 5.16 | Self-report and clinician-rated measures of depression severity: can one replace the other? ( Dernovšek, MZ; Farmer, A; Henigsberg, N; Maier, W; McGuffin, P; Mors, O; Perlis, RH; Placentino, A; Uher, R, 2012) |
| " The aim of the present genome-wide association study was to identify additional genetic variants involved in increasing suicidal ideation during escitalopram and nortriptyline treatment." | 5.16 | Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project. ( Aitchison, KJ; Breen, G; Craig, IW; Dernovsek, MZ; Farmer, A; Gennarelli, M; Guipponi, M; Hauser, J; Henigsberg, N; Lathrop, M; Lewis, CM; Maier, W; McGuffin, P; Mors, O; Ng, MY; Perroud, N; Rietschel, M; Souery, D; Stamp, AS; Uher, R, 2012) |
| "Higher BMI and obesity predicted poor response to nortriptyline but did not significantly influence response to escitalopram." | 5.14 | Body weight as a predictor of antidepressant efficacy in the GENDEP project. ( Aitchison, KJ; Dernovsek, MZ; Farmer, A; Gunasinghe, C; Hauser, J; Henigsberg, N; Kalember, P; Kozel, D; Larsen, ER; Leszczynska-Rodziewicz, A; Linotte, S; Maier, W; McGuffin, P; Mors, O; Pedrini, L; Perroud, N; Placentino, A; Rietschel, M; Souery, D; Strohmaier, J; Uher, R; Zobel, A, 2009) |
| "To compare weight loss after birth in women who took the antidepressants nortriptyline or sertraline or placebo in 2 clinical studies designed to prevent recurrent postpartum major depression." | 5.11 | Weight changes in postpartum women with remitted depression. ( Gracious, BL; Hanusa, BH; Peindl, KS; Perel, JM; Wisner, KL, 2005) |
| "In the PIT group, the initial TCA dosage was based on CYP2D6 and CYP2C19 genotypes." | 3.30 | Effectiveness of Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder: A Randomized Clinical Trial. ( Aarnoutse, RE; Coenen, MJH; Donders, R; Grotenhuis, AJ; Janzing, JGE; Kievit, W; Mihaescu, R; Schellekens, AFA; Spijker, J; Ter Hark, SE; van der Meij, A; Vos, CF, 2023) |
| "Patients with major depressive disorder and an indication for ECT received either nortriptyline or placebo during a bilateral ECT course." | 3.11 | Influence of adjuvant nortriptyline on the efficacy of electroconvulsive therapy: A randomized controlled trial and 1-year follow-up. ( Birkenhäger, TK; Hoogendijk, WJG; Kamperman, AM; Pluijms, EM; van den Broek, WW, 2022) |
| "For patients with major depressive disorder (MDD) experiencing side-effects or non-response to their first antidepressant, little is known regarding the effect of switching between a tricyclic antidepressant (TCA) and a selective serotonin reuptake inhibitor (SSRI)." | 2.90 | Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder. ( Aitchison, KJ; Buttenschøn, HN; Farmer, A; Hauser, J; Köhler-Forsberg, O; Larsen, ER; Maier, W; McGuffin, P; Mors, O; Rietschel, M; Souery, D; Uher, R, 2019) |
| "Suicidal ideation is a frequent and difficult-to-treat clinical challenge among patients with major depressive disorder (MDD)." | 2.90 | Trajectories of Suicidal Ideation During 12 Weeks of Escitalopram or Nortriptyline Antidepressant Treatment Among 811 Patients With Major Depressive Disorder. ( Aitchison, KJ; Behrendt-Møller, I; Buttenschøn, HN; Dernovsek, MZ; Hauser, J; Henigsberg, N; Köhler-Forsberg, O; Madsen, T; Maier, W; McGuffin, P; Mors, O; Perroud, N; Rietschel, M; Souery, D; Uher, R, 2019) |
| " Patients with deviant genotype (that is poor, intermediate or ultrarapid genotype) will be randomly allocated to an intervention group in which the genotype and dosing advice is communicated to the treating physician, or to a control group in which patients receive care as usual." | 2.80 | Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial). ( Berm, EJ; Boshuisen, M; Breuning, L; Brouwers, JR; Dhondt, T; Hak, E; Jansen, PA; Kok, RM; Maring, JG; Mulder, H; Postma, M; Risselada, AJ; van Marum, R; Venema, H; Vleugel, L; Voshaar, RC; Wilffert, B, 2015) |
| " By study phase, Eight of 27 (30%) patients remitted with initial dosing of tranylcypromine up to 60 mg/d, 6/18 (33%) remitted with above PDR dosing of tranylcypromine up to 120 mg/d, and 1/6 (17%) to adding dextroamphetamine." | 2.79 | How treatable is refractory depression? ( Deliyannides, DA; McGrath, PJ; Stewart, JW, 2014) |
| "We tested nine symptom dimensions derived from a previously published factor analysis of depression rating scales as predictors of outcome in 811 adults with moderate to severe depression treated with flexibly dosed escitalopram or nortriptyline in Genome-based Therapeutic Drugs for Depression (GENDEP)." | 2.77 | Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. ( Aitchison, KJ; Bajs, M; Dernovsek, MZ; Farmer, A; Hauser, J; Henigsberg, N; Maier, W; McGuffin, P; Mors, O; Perlis, RH; Rietschel, M; Souery, D; Uher, R; Zobel, A, 2012) |
| "Personality disorders are neither particularly stable nor treatment resistant." | 2.75 | Personality disorders improve in patients treated for major depression. ( Frampton, CM; Joyce, PR; Mulder, RT, 2010) |
| "A total of 796 adult patients with major depressive disorder who were treated with a flexible dosage of escitalopram or nortriptyline in Genome-based Therapeutic Drugs for Depression (GENDEP) were included in the sample and provided data on suicidal ideation." | 2.74 | Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. ( Aitchison, KJ; Bonvicini, C; Craig, I; Farmer, AE; Gray, J; Gupta, B; Hauser, J; Henigsberg, N; Huezo-Diaz, P; Jorgensen, L; Kalember, P; Kapelski, P; Lewis, CM; Maier, W; Marusic, A; McGuffin, P; Mors, O; Perroud, N; Petrovic, A; Placentino, A; Rietschel, M; Schulze, TG; Smith, R; Souery, D; Uher, R; Zobel, A, 2009) |
| "Relapse was assessed with the 24-item Hamilton Rating Scale for Depression." | 2.74 | Is baseline medication resistance associated with potential for relapse after successful remission of a depressive episode with ECT? Data from the Consortium for Research on Electroconvulsive Therapy (CORE). ( Bailine, SH; Fink, M; Husain, MM; Kellner, CH; Knapp, RG; Mueller, M; Petrides, G; Rasmussen, KG; Rummans, TA; Sampson, SM, 2009) |
| "Treatment with nortriptyline enhanced the efficacy and reduced the cognitive adverse effects of ECT relative to placebo." | 2.74 | Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects. ( Cooper, T; Dillingham, EM; Garcia, K; Haskett, RF; Isenberg, K; McCall, WV; Mulsant, BH; Prudic, J; Rosenquist, P; Sackeim, HA, 2009) |
| "The T allele of GNbeta3, borderline personality disorder and childhood sexual abuse were all significantly associated with self-mutilation in depressed patients." | 2.72 | Genetic, developmental and personality correlates of self-mutilation in depressed patients. ( Joyce, PR; Kennedy, MA; Luty, SE; McKenzie, JM; Miller, AL; Mulder, RT; Sullivan, PF, 2006) |
| "Patients with major depressive disorder (MDD) may have significant differences in cholesterol levels compared with healthy controls." | 2.71 | Serum cholesterol in treatment-resistant depression. ( Alpert, JE; Fava, M; Iosifescu, DV; Merens, W; Nierenberg, AA; Papakostas, GI; Petersen, T; Sonawalla, SB, 2003) |
| "Patients with major depression (ICD 10: F31-F33) and a HAMD-21 total score of 15-41 received At on a dosage schedule chosen by the doctor for at least 4 wks." | 2.71 | Predictors of therapeutic effects in amitriptyline treatment--1. Plasma drug levels. ( Franke, L; Müller-Oerlinghausen, B; Schewe, HJ; Uebelhack, R, 2003) |
| "Melancholia was associated with reduced activity in the subgenual PFC (Brodmann area 25), manifested by increased inhibitory delta activity (1." | 2.71 | Functional but not structural subgenual prefrontal cortex abnormalities in melancholia. ( Abercrombie, HC; Benca, RM; Chung, MK; Davidson, RJ; Fox, AS; Larson, CL; Oakes, TR; Pizzagalli, DA; Schaefer, SM, 2004) |
| "Fifty-three elderly subjects with major depressive disorder according to DSM-IV criteria who failed treatment with paroxetine plus interpersonal psychotherapy received 1 to 3 trials of augmentation with bupropion sustained release, nortriptyline, or lithium." | 2.71 | Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors. ( Basinski, J; Begley, A; Dew, MA; Farhi, P; Mulsant, BH; Reynolds, CF; Whyte, EM, 2004) |
| " The efficacy was assessed using the 17-item Hamilton Rating Scale for Depression (HAM-D), Clinical Global Impression Scale (CGI) severity and improvement scores, while the safety profiles were assessed using the UKU Side Effect Rating Scale at baseline, and on days 7, 14, 28 and 56." | 2.71 | A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression. ( Akimoto, Y; Aoyama, H; Kamijima, K; Koda, R; Mimura, M; Nakagome, K; Otsubo, T; Tanaka, K; Yamada, H, 2005) |
| "Nortriptyline was also associated with a significant decrease in nonlinearity scores, which may be due to anticholinergic and/or sympatholytic effects." | 2.70 | Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. ( Mallavarapu, M; Pesce, V; Radhakrishna, RK; Roose, S; Yeragani, VK, 2002) |
| "Major depressive disorder is one of the most common mental disorders in children and adolescents." | 2.53 | Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. ( Cipriani, A; Coghill, D; Cohen, D; Cuijpers, P; Del Giovane, C; Hazell, P; Hetrick, SE; Leucht, S; Liu, L; Liu, Y; Michael, KD; Pu, J; Qin, B; Ravindran, AV; Whittington, C; Xie, P; Yang, L; Zhang, Y; Zhou, X, 2016) |
| "Current pharmacological treatments for major depressive disorder (MDD) are ineffective in a significant proportion of patients, and the identification of new antidepressant compounds has been difficult." | 1.46 | Transcriptomic profiling of human hippocampal progenitor cells treated with antidepressants and its application in drug repositioning. ( Breen, G; Lee, SH; Murphy, T; Powell, TR; Price, J; Thuret, S, 2017) |
| " In the primary analysis, fluoxetine 40mg/day was equivalent to paroxetine dosage of 34." | 1.42 | Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. ( Barbui, C; Cipriani, A; Furukawa, TA; Hayasaka, Y; Leucht, S; Magni, LR; Ogawa, Y; Purgato, M; Takeshima, N, 2015) |
| "Nortriptyline is a NET-selective tricyclic antidepressant (TCAs) that has been widely used for the treatment of depression." | 1.40 | Norepinephrine transporter occupancy by nortriptyline in patients with depression: a positron emission tomography study with (S,S)-[¹⁸F]FMeNER-D₂. ( Arakawa, R; Fujiwara, H; Ito, H; Kato, M; Kawamura, K; Kimura, Y; Kodaka, F; Murakami, Y; Nagashima, T; Nogami, T; Okubo, Y; Shimada, H; Suhara, T; Suzuki, M; Takahashi, H; Takahata, K; Takano, H; Tateno, A; Yamada, M; Zhang, MR, 2014) |
| "Major depressive disorder is associated with increased cardiac mortality." | 1.36 | Reduced cardio-respiratory coupling after treatment with nortriptyline in contrast to S-citalopram. ( Bär, KJ; Höfels, S; Maier, W; Schuhmacher, A; Schulz, S; Voss, A; Yeragani, VK; Zobel, A, 2010) |
| "All patients had a diagnosis of major depressive disorder as defined by DSM-III or DSM-IV criteria." | 1.35 | An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. ( Campbell, GM; Case, M; Corya, SA; Henley, DB; Osuntokun, O; Thase, ME; Trivedi, MH; Watson, SB, 2009) |
| "Subsequent seizures were induced at a level 50% higher than the empirically determined ST." | 1.35 | Seizure threshold in a large sample: implications for stimulus dosing strategies in bilateral electroconvulsive therapy: a report from CORE. ( Bailine, S; Braga, RJ; Fink, M; Husain, M; Kellner, C; Knapp, R; Malur, C; Mueller, M; O'Connor, K; Petrides, G; Rummans, T, 2009) |
| "The subjects were 313 patients with major depressive disorder and 17-item Hamilton Rating Scale for Depression (HAM-D-17) scores between 14 and 25 who were treated for 6 months with either pharmacotherapy, short-term psychodynamic supportive psychotherapy or combined therapy." | 1.35 | Identifying patients at risk of complete nonresponse in the outpatient treatment of depression. ( Dekker, J; Peen, J; Schoevers, RA; van Aalst, G; Van, HL, 2008) |
| " For depressive neurosis and involutional melancholia best therapeutic responses were yielded at a dosage of 50 mg, while in the treatment of manic-depressive illness, comparable results occurred at a 150 mg dosage." | 1.26 | Amitriptyline, nortriptyline plasma levels and clinical response in women with affective disorders. ( Corona, GL; Cucchi, ML; Fenoglio, L; Frattini, P; Pinelli, P; Santagostino, G; Zerbi, F, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (4.86) | 18.7374 |
| 1990's | 8 (5.56) | 18.2507 |
| 2000's | 71 (49.31) | 29.6817 |
| 2010's | 52 (36.11) | 24.3611 |
| 2020's | 6 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Köhler-Forsberg, O | 3 |
| Keers, R | 4 |
| Uher, R | 27 |
| Hauser, J | 20 |
| Maier, W | 21 |
| Rietschel, M | 19 |
| McGuffin, P | 24 |
| Farmer, AE | 6 |
| Aitchison, KJ | 18 |
| Mors, O | 24 |
| Pluijms, EM | 2 |
| Kamperman, AM | 2 |
| Hoogendijk, WJG | 1 |
| van den Broek, WW | 1 |
| Birkenhäger, TK | 2 |
| Ter Hark, SE | 2 |
| Vos, CF | 2 |
| Aarnoutse, RE | 2 |
| Schene, AH | 1 |
| Coenen, MJH | 2 |
| Janzing, JGE | 2 |
| Schrag, A | 2 |
| Carroll, C | 2 |
| Duncan, G | 2 |
| Molloy, S | 2 |
| Grover, L | 2 |
| Hunter, R | 2 |
| Brown, R | 2 |
| Freemantle, N | 2 |
| Whipps, J | 2 |
| Serfaty, MA | 2 |
| Lewis, G | 2 |
| Vinther, PT | 1 |
| Schellekens, AFA | 1 |
| Spijker, J | 1 |
| van der Meij, A | 1 |
| Grotenhuis, AJ | 1 |
| Mihaescu, R | 1 |
| Kievit, W | 1 |
| Donders, R | 1 |
| Spaans, HP | 3 |
| Kok, RM | 8 |
| Bouckaert, F | 3 |
| Van Den Berg, JF | 3 |
| Tunney, OC | 1 |
| Sienaert, P | 3 |
| Verwijk, E | 3 |
| Kho, KH | 3 |
| Stek, ML | 3 |
| Jaracz, J | 1 |
| Gattner, K | 1 |
| Jaracz, K | 1 |
| Górna, K | 1 |
| Moczko, J | 1 |
| Iniesta, R | 2 |
| Hodgson, K | 2 |
| Stahl, D | 2 |
| Malki, K | 2 |
| Henigsberg, N | 19 |
| Dernovsek, MZ | 10 |
| Souery, D | 16 |
| Dobson, R | 3 |
| Farmer, A | 14 |
| Lewis, CM | 7 |
| Zwicker, A | 1 |
| Fabbri, C | 1 |
| Zobel, A | 12 |
| Larsen, ER | 7 |
| Buttenschøn, HN | 3 |
| Madsen, T | 1 |
| Behrendt-Møller, I | 1 |
| Perroud, N | 6 |
| Bech, P | 2 |
| Allerup, P | 1 |
| Csillag, C | 1 |
| Licht, RW | 2 |
| Kessing, LV | 1 |
| Bukh, JD | 1 |
| Powell, TR | 3 |
| Smith, RG | 1 |
| Hackinger, S | 1 |
| Schalkwyk, LC | 1 |
| Mill, J | 1 |
| Tansey, KE | 3 |
| Sneed, JR | 1 |
| Reinlieb, ME | 1 |
| Rutherford, BR | 1 |
| Miyazaki, M | 1 |
| Fitzsimons, L | 1 |
| Turret, N | 1 |
| Pelton, GH | 1 |
| Devanand, DP | 1 |
| Sackeim, HA | 5 |
| Roose, SP | 2 |
| Takano, H | 1 |
| Arakawa, R | 1 |
| Nogami, T | 1 |
| Suzuki, M | 1 |
| Nagashima, T | 1 |
| Fujiwara, H | 1 |
| Kimura, Y | 1 |
| Kodaka, F | 1 |
| Takahata, K | 1 |
| Shimada, H | 1 |
| Murakami, Y | 1 |
| Tateno, A | 1 |
| Yamada, M | 1 |
| Ito, H | 1 |
| Kawamura, K | 1 |
| Zhang, MR | 1 |
| Takahashi, H | 1 |
| Kato, M | 1 |
| Okubo, Y | 1 |
| Suhara, T | 1 |
| Stewart, JW | 1 |
| Deliyannides, DA | 1 |
| McGrath, PJ | 2 |
| Dew, T | 1 |
| Alampay, MM | 1 |
| Haigney, MC | 1 |
| Flanagan, MC | 1 |
| Perito, RM | 1 |
| Love, KM | 1 |
| Grammer, GG | 1 |
| Berm, EJJ | 1 |
| Paardekooper, J | 1 |
| Brummel-Mulder, E | 1 |
| Hak, E | 2 |
| Wilffert, B | 2 |
| Maring, JG | 2 |
| Berm, EJ | 1 |
| Postma, M | 1 |
| Boshuisen, M | 1 |
| Breuning, L | 1 |
| Brouwers, JR | 1 |
| Dhondt, T | 1 |
| Jansen, PA | 1 |
| van Marum, R | 1 |
| Mulder, H | 1 |
| Voshaar, RC | 1 |
| Risselada, AJ | 1 |
| Venema, H | 1 |
| Vleugel, L | 1 |
| Kunte, H | 1 |
| Rentzsch, J | 1 |
| Kronenberg, G | 1 |
| Kellner, CH | 5 |
| Geduldig, ET | 1 |
| Knapp, RG | 5 |
| Young, RC | 3 |
| Weiner, RD | 1 |
| Greenberg, RM | 2 |
| Prudic, J | 4 |
| McCall, WV | 3 |
| Petrides, G | 6 |
| Husain, MM | 5 |
| Rudorfer, MV | 1 |
| Lisanby, SH | 1 |
| Hayasaka, Y | 1 |
| Purgato, M | 1 |
| Magni, LR | 1 |
| Ogawa, Y | 1 |
| Takeshima, N | 1 |
| Cipriani, A | 2 |
| Barbui, C | 1 |
| Leucht, S | 2 |
| Furukawa, TA | 1 |
| Foldager, L | 1 |
| Elfving, B | 1 |
| Poulsen, PH | 1 |
| Martiny, K | 1 |
| Nielsen, CT | 1 |
| Damkier, P | 1 |
| Refsgaard, E | 1 |
| Lunde, M | 1 |
| Straasø, B | 1 |
| Christensen, EM | 1 |
| Lolk, A | 1 |
| Holmskov, J | 1 |
| Sørensen, CH | 1 |
| Brødsgaard, I | 1 |
| Eftekhari, SZ | 1 |
| Bendsen, BB | 1 |
| Klysner, R | 1 |
| Terp, IM | 1 |
| Larsen, JK | 1 |
| Vestergaard, P | 1 |
| Buchholtz, PE | 1 |
| Gram, LF | 1 |
| Coppola, G | 1 |
| Zvezdana Dernovšek, M | 1 |
| Placentino, A | 11 |
| Craig, IW | 2 |
| Breen, G | 4 |
| Fawcett, J | 1 |
| Rush, AJ | 2 |
| Vukelich, J | 1 |
| Diaz, SH | 1 |
| Dunklee, L | 1 |
| Romo, P | 1 |
| Yarns, BC | 1 |
| Escalona, R | 1 |
| Cattaneo, A | 1 |
| Ferrari, C | 1 |
| Bocchio-Chiavetto, L | 1 |
| Riva, MA | 1 |
| Pariante, CM | 1 |
| Zhou, X | 1 |
| Del Giovane, C | 1 |
| Hetrick, SE | 1 |
| Qin, B | 1 |
| Whittington, C | 1 |
| Coghill, D | 1 |
| Zhang, Y | 1 |
| Hazell, P | 1 |
| Cuijpers, P | 1 |
| Pu, J | 1 |
| Cohen, D | 1 |
| Ravindran, AV | 1 |
| Liu, Y | 1 |
| Michael, KD | 1 |
| Yang, L | 1 |
| Liu, L | 1 |
| Xie, P | 1 |
| Murphy, T | 1 |
| Lee, SH | 1 |
| Price, J | 1 |
| Thuret, S | 1 |
| Navarro, V | 4 |
| Gastó, C | 4 |
| Torres, X | 2 |
| Masana, G | 2 |
| Penadés, R | 1 |
| Guarch, J | 1 |
| Vázquez, M | 1 |
| Serra, M | 2 |
| Pujol, N | 1 |
| Pintor, L | 1 |
| Catalán, R | 1 |
| Alexopoulos, GS | 3 |
| Van, HL | 1 |
| Dekker, J | 1 |
| Peen, J | 1 |
| van Aalst, G | 1 |
| Schoevers, RA | 1 |
| Nolen, WA | 3 |
| Heeren, TJ | 4 |
| Rasmussen, KG | 3 |
| Mueller, M | 4 |
| Rummans, TA | 4 |
| Fink, M | 6 |
| Sampson, SM | 1 |
| Bailine, SH | 3 |
| Kozel, D | 6 |
| Strohmaier, J | 3 |
| Leszczynska-Rodziewicz, A | 1 |
| Kalember, P | 3 |
| Pedrini, L | 1 |
| Linotte, S | 1 |
| Gunasinghe, C | 1 |
| Trivedi, MH | 2 |
| Thase, ME | 3 |
| Osuntokun, O | 1 |
| Henley, DB | 1 |
| Case, M | 2 |
| Watson, SB | 1 |
| Campbell, GM | 1 |
| Corya, SA | 2 |
| Lanza di Scalea, T | 1 |
| Hanusa, BH | 2 |
| Wisner, KL | 3 |
| van Baarsen, C | 1 |
| Harley, J | 1 |
| Roberts, R | 1 |
| Joyce, P | 1 |
| Mulder, R | 1 |
| Luty, S | 1 |
| Frampton, C | 1 |
| Kennedy, M | 1 |
| Johnstone, JM | 1 |
| Luty, SE | 8 |
| Carter, JD | 2 |
| Mulder, RT | 9 |
| Frampton, CM | 2 |
| Joyce, PR | 9 |
| Dillingham, EM | 1 |
| Cooper, T | 1 |
| Rosenquist, P | 1 |
| Isenberg, K | 2 |
| Garcia, K | 1 |
| Mulsant, BH | 16 |
| Haskett, RF | 2 |
| Smith, R | 2 |
| Huezo-Diaz, P | 2 |
| Marusic, A | 1 |
| Kapelski, P | 1 |
| Bonvicini, C | 2 |
| Jorgensen, L | 2 |
| Petrovic, A | 2 |
| Schulze, TG | 3 |
| Gupta, B | 3 |
| Gray, J | 1 |
| Craig, I | 4 |
| Dmitrzak-Weglarz, M | 2 |
| Kovacic, Z | 2 |
| Giovannini, C | 3 |
| Mendlewicz, J | 5 |
| Braga, RJ | 1 |
| Knapp, R | 1 |
| Husain, M | 1 |
| Rummans, T | 1 |
| Bailine, S | 1 |
| Malur, C | 2 |
| O'Connor, K | 2 |
| Kellner, C | 1 |
| Smith, GE | 2 |
| Cullum, CM | 1 |
| Felmlee-Devine, MD | 1 |
| Bernstein, HJ | 2 |
| O'Connor, MK | 2 |
| Sampson, S | 2 |
| Jaffee, S | 1 |
| Hoda, F | 1 |
| Ng, MY | 2 |
| Zagar, T | 1 |
| Czerski, PM | 1 |
| Jerman, B | 1 |
| Cohen-Woods, S | 1 |
| Pirlo, K | 1 |
| Butler, AW | 1 |
| Muglia, P | 1 |
| Barnes, MR | 1 |
| Lathrop, M | 2 |
| Spittlehouse, JK | 1 |
| Pearson, JF | 1 |
| McKenzie, JM | 5 |
| Bär, KJ | 1 |
| Schuhmacher, A | 1 |
| Höfels, S | 1 |
| Schulz, S | 1 |
| Voss, A | 1 |
| Yeragani, VK | 3 |
| Skibinska, M | 1 |
| Kristensen, AS | 1 |
| Kumar, S | 1 |
| Kok, R | 1 |
| Heeren, T | 1 |
| Nolen, W | 1 |
| Dobkin, RD | 1 |
| Menza, M | 1 |
| Bienfait, KL | 1 |
| Gara, M | 1 |
| Marin, H | 1 |
| Mark, MH | 1 |
| Dicke, A | 1 |
| Friedman, J | 1 |
| Scassellati, C | 1 |
| Schmäl, C | 2 |
| Szczepankiewicz, A | 1 |
| Elkin, A | 1 |
| Gennarelli, M | 2 |
| Guipponi, M | 1 |
| Stamp, AS | 1 |
| Rosenquist, PB | 1 |
| Kimball, J | 1 |
| Haskett, R | 1 |
| Lasater, B | 1 |
| Wüst, S | 1 |
| Streit, F | 1 |
| Sit, D | 1 |
| Perel, JM | 5 |
| Wisniewski, SR | 2 |
| Helsel, JC | 1 |
| Luther, JF | 2 |
| Perlis, RH | 2 |
| Bajs, M | 1 |
| Rajewska-Rager, A | 1 |
| Carver, S | 1 |
| Power, RA | 2 |
| Muthén, B | 1 |
| Datto, CJ | 1 |
| Oslin, DW | 1 |
| Streim, JE | 1 |
| Scheinthal, SM | 1 |
| DiFilippo, S | 1 |
| Katz, IR | 1 |
| Pesce, V | 2 |
| Jayaraman, A | 1 |
| Roose, S | 2 |
| Mallavarapu, M | 1 |
| Radhakrishna, RK | 1 |
| Marcos, T | 2 |
| Portella, MJ | 2 |
| Torra, M | 1 |
| Rodamilans, M | 1 |
| Nierenberg, AA | 4 |
| Papakostas, GI | 3 |
| Petersen, T | 3 |
| Montoya, HD | 1 |
| Worthington, JJ | 1 |
| Tedlow, J | 1 |
| Alpert, JE | 4 |
| Fava, M | 4 |
| Sonawalla, SB | 1 |
| Merens, W | 1 |
| Iosifescu, DV | 2 |
| Szanto, K | 3 |
| Houck, P | 1 |
| Dew, MA | 10 |
| Reynolds, CF | 20 |
| Roffi, PA | 1 |
| Rosenbaum, JF | 1 |
| Franke, L | 1 |
| Schewe, HJ | 1 |
| Uebelhack, R | 1 |
| Müller-Oerlinghausen, B | 1 |
| PELZMAN, O | 1 |
| BARRON, A | 1 |
| RUDY, LH | 1 |
| SMITH, JA | 1 |
| LANG, HB | 1 |
| Miller, AL | 3 |
| Rogers, GR | 1 |
| Kennedy, MA | 4 |
| Adeoye, OM | 1 |
| Ferrell, RE | 1 |
| Kirshner, MA | 1 |
| Seligman, K | 1 |
| Begley, AE | 6 |
| Pollock, BG | 9 |
| Pizzagalli, DA | 1 |
| Oakes, TR | 1 |
| Fox, AS | 1 |
| Chung, MK | 1 |
| Larson, CL | 1 |
| Abercrombie, HC | 1 |
| Schaefer, SM | 1 |
| Benca, RM | 1 |
| Davidson, RJ | 1 |
| Roberts, RL | 1 |
| McIntosh, VV | 1 |
| Carter, FA | 1 |
| Bulik, CM | 1 |
| Sullivan, PF | 2 |
| Houck, PR | 11 |
| Mazumdar, S | 9 |
| Koru-Sengul, T | 1 |
| Tang, G | 1 |
| Whyte, EM | 3 |
| Basinski, J | 1 |
| Farhi, P | 1 |
| Begley, A | 2 |
| Otsubo, T | 1 |
| Akimoto, Y | 1 |
| Yamada, H | 1 |
| Koda, R | 1 |
| Aoyama, H | 1 |
| Tanaka, K | 1 |
| Mimura, M | 1 |
| Nakagome, K | 1 |
| Kamijima, K | 2 |
| Gracious, BL | 1 |
| Peindl, KS | 1 |
| Porter, RJ | 2 |
| Gildengers, AG | 1 |
| Aizenstein, HJ | 1 |
| Jones, BL | 1 |
| Greenhouse, J | 1 |
| Rami, L | 1 |
| Lázaro, L | 1 |
| Salamero, M | 1 |
| Morse, JQ | 1 |
| Pilkonis, PA | 1 |
| Frank, E | 7 |
| Shelton, RC | 1 |
| Williamson, DJ | 1 |
| Sanger, TM | 1 |
| Van Campen, LE | 1 |
| Briggs, SD | 1 |
| Tollefson, GD | 1 |
| Loughhead, AM | 1 |
| Stowe, ZN | 1 |
| Newport, DJ | 1 |
| Ritchie, JC | 1 |
| DeVane, CL | 1 |
| Owens, MJ | 1 |
| Hensley, PL | 1 |
| Lavori, PW | 1 |
| Pilhatsch, MK | 1 |
| Burghardt, R | 1 |
| Wandinger, KP | 1 |
| Bauer, M | 1 |
| Adli, M | 1 |
| Blanch, J | 1 |
| Mowla, A | 1 |
| Ghanizadeh, A | 1 |
| Pani, A | 1 |
| Dombrovski, AY | 1 |
| Blakesley-Ball, RE | 1 |
| Warden, D | 1 |
| Biggs, M | 2 |
| Niederehe, G | 1 |
| Ritz, L | 1 |
| Kim, H | 1 |
| Lim, SW | 1 |
| Kim, S | 1 |
| Kim, JW | 1 |
| Chang, YH | 1 |
| Carroll, BJ | 1 |
| Kim, DK | 1 |
| Tew, JD | 1 |
| Lenze, EJ | 4 |
| Miller, MD | 8 |
| Stack, JA | 4 |
| Bensasi, S | 2 |
| Rasmussen, K | 1 |
| Smith, G | 1 |
| Yim, E | 1 |
| McClintock, S | 1 |
| Janssen, J | 1 |
| Hulshoff Pol, HE | 1 |
| Schnack, HG | 1 |
| Lampe, IK | 1 |
| de Leeuw, FE | 1 |
| Kahn, RS | 1 |
| Biggs, MM | 1 |
| Hollister, LE | 1 |
| Pfefferbaum, A | 1 |
| Davis, KL | 1 |
| Corona, GL | 1 |
| Pinelli, P | 1 |
| Zerbi, F | 1 |
| Fenoglio, L | 1 |
| Santagostino, G | 1 |
| Frattini, P | 1 |
| Cucchi, ML | 1 |
| Ghaemi, SN | 1 |
| Kirkwood, CK | 1 |
| Miller, M | 1 |
| Kupfer, DJ | 4 |
| Kalayam, B | 1 |
| Nambudiri, DE | 1 |
| Kakuma, T | 2 |
| Tan, RS | 1 |
| Brown, C | 1 |
| Schulberg, HC | 1 |
| Sacco, D | 1 |
| Taylor, MP | 1 |
| Cornes, C | 3 |
| Marraccini, RL | 1 |
| Morita, S | 1 |
| Shimoda, K | 1 |
| Someya, T | 1 |
| Yoshimura, Y | 1 |
| Kato, N | 1 |
| Flint, AJ | 1 |
| Rifat, SL | 1 |
| Mamo, DC | 1 |
| Sweet, RA | 1 |
| Weber, E | 1 |
| Stack, J | 1 |
| Mulsant, B | 1 |
| Dhar, AK | 1 |
| Hull, J | 1 |
| Bump, GM | 1 |
| Weintraub, D | 2 |
| Mann, JJ | 1 |
| Pettinati, HM | 1 |
| Crowe, RR | 1 |
| Cooper, TB | 1 |
| Geller, B | 1 |
| Zimerman, B | 1 |
| Williams, M | 1 |
| Bolhofner, K | 1 |
| Craney, JL | 1 |
| Nebes, RD | 1 |
| Butters, MA | 2 |
| Zmuda, MD | 2 |
| Aizenstein, H | 1 |
| Alpert, M | 1 |
| Pouget, ER | 1 |
| Silva, RR | 1 |
| Fabian, TJ | 1 |
| Linares, AM | 1 |
| Trottini, M | 1 |
| Kroboth, PD | 1 |
| Martire, LM | 1 |
| Schulz, R | 1 |
| Stolar, AG | 1 |
| Stewart, JT | 1 |
| Imber, SD | 1 |
| Escande, M | 1 |
| Gayral, L | 1 |
| Roux, G | 1 |
| Oulès, J | 1 |
| Bacciochi, M | 1 |
| Sedivec, V | 1 |
| Valenová, Z | 1 |
| Paceltová, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Treatment for Refractory Depression With Sequential Trials of Tranylcypromine, Tranylcypromine Plus Dextroamphetamine, Tranylcypromine Plus Triiodothyronine.[NCT00296686] | Phase 4 | 31 participants (Actual) | Interventional | 2001-09-30 | Terminated (stopped due to Study is no longer funded.) | ||
| Effects and Cost-Effectiveness of Pharmacogenetic Screening Among Elderly Starters With Antidepressants: A Pragmatic Randomized Controlled Trial[NCT01778907] | Phase 4 | 202 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Escitalopram and Language Intervention for Subacute Aphasia (ELISA)[NCT03843463] | Phase 2 | 88 participants (Anticipated) | Interventional | 2021-07-18 | Recruiting | ||
| Relapse Prevention in Patients With a Major Depressive Episode Treated With Electroconvulsive Treatment Using a Fixed Dose Range of Escitalopram Compared to a Fixed Dose of Nortriptyline (DUAG-7) A Randomised Controlled 6 Month Double-blind Study[NCT00660062] | Phase 4 | 47 participants (Actual) | Interventional | 2009-08-31 | Terminated (stopped due to Slow inclusion) | ||
| Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) a Multicentre Open-label Randomized Controlled Trial Protocol[NCT05814640] | Phase 1/Phase 2 | 520 participants (Anticipated) | Interventional | 2023-02-20 | Recruiting | ||
| Development and Evaluation of an Ecological Momentary Assessment (EMA) Baseline Screening System for Therapists Who Treat Youths With Depressive Symptoms[NCT04830527] | 60 participants (Actual) | Interventional | 2020-11-24 | Terminated (stopped due to The study was terminated early due to the difficulty in recruiting cases during a pandemic period.) | |||
| Exploring Alterations of Central Autonomic Modulation in Patients With Bipolar Depression[NCT01213121] | Phase 4 | 60 participants (Anticipated) | Interventional | 2010-09-30 | Recruiting | ||
| Treatment of Depression in Patients With Parkinson's Disease[NCT00062738] | Phase 2 | 52 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Antidepressant Use During Pregnancy[NCT00279370] | 283 participants (Actual) | Observational | 1999-09-30 | Completed | |||
| Sequenced Treatment Alternatives to Relieve Depression[NCT00021528] | Phase 4 | 4,000 participants | Interventional | 2001-07-31 | Completed | ||
| Prediction of the Therapeutic Response in Depression Based on an Early Neuro-computational Modeling Assessment of Motivation[NCT05866575] | 136 participants (Anticipated) | Interventional | 2023-06-01 | Not yet recruiting | |||
| Study of Antidepressants in Parkinson's Disease[NCT00086190] | Phase 3 | 115 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Genetics of Self-injurious Behaviour[NCT05563324] | 234 participants (Actual) | Observational | 2014-05-09 | Completed | |||
| Influences on and Prevention of Self-harm Behaviour Among the Most At-risk Adolescents[NCT05765864] | 400 participants (Anticipated) | Observational | 2023-03-23 | Recruiting | |||
| Randomised Controlled Trial of Electroconvulsive Therapy (ECT) With Pharmacotherapy or Pharmacotherapy Alone in Relapse Prevention of Depression[NCT00627887] | Phase 4 | 56 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Phase 1 Study: Evaluation of Three Continuation Therapies After Acute Electroconvusive Therapy (ECT) Concerning Efficacy and Cognition in Severly Depressed Patients[NCT00437385] | Phase 1 | 90 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Changing Tactics? Optimizing ECT in Difficult-to-treat Depression: A Randomized Trial Comparing Continuation of Right Unilateral ECT and Switching to Bitemporal ECT in Case of Early Non-response During an Acute Course of ECT for Difficult-to-treat Depress[NCT05923801] | 196 participants (Anticipated) | Interventional | 2023-06-01 | Recruiting | |||
| Prolonging Remission in Depressed Elderly (PRIDE)[NCT01028508] | Phase 4 | 247 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Comparing Therapeutic Efficacy and Cognitive Side Effects of Electroconvulsive Therapy (ECT) Using Ketamine Versus Methohexital Anesthesia[NCT01881763] | Phase 4 | 31 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Optimization of Electroconvulsive Therapy[NCT00045916] | Phase 4 | 340 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| [NCT00000369] | Phase 3 | 0 participants | Interventional | 1997-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
total score on HDRS (0-54 higher score is worse) (NCT00062738)
Timeframe: 8 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Nortriptyline | 10.84 |
| Paroxetine | 12.45 |
| Placebo | 15.81 |
Percent of patients who had a 50% decrease in total HDRS at 8 weeks (NCT00062738)
Timeframe: 8 weeks
| Intervention | percent of patients who were responders (Number) |
|---|---|
| Nortriptyline | 53 |
| Paroxetine | 11 |
| Placebo | 24 |
Beck Depression Inventory II ranges from 0-63. Higher score indicates more severe depression. 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, 29-63 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in BDI-II score (Mean) |
|---|---|
| Paroxetine | -9.7 |
| Venlafaxine Extended Release | -9.6 |
| Placebo | -5.2 |
Brief Psychiatric Rating Scale. Maximum score 126. Higher score indicates greater psychiatric difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in BPRS score (Mean) |
|---|---|
| Paroxetine | -9.0 |
| Venlafaxine Extended Release | -9.8 |
| Placebo | -4.4 |
Geriatric Depression Scale ranges from 0-30. Higher score indicates more severe depression. 0-9 normal, 10-19 mild depression, 20-30 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in GDS score (Mean) |
|---|---|
| Paroxetine | -6.9 |
| Venlafaxine Extended Release | -6.9 |
| Placebo | -2.8 |
Change in Hamilton Rating Scale for Depression over 12 weeks. Hamilton Depression Rating Scale ranges from 0-50. Higher scores represent more significant depression. Mild depression ranges from 8-13, moderate depression from 14-18, severe 19-22 and very severe any score over 23. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in HAM-D score (Mean) |
|---|---|
| Paroxetine | -13.0 |
| Venlafaxine Extended Release | -11.0 |
| Placebo | -6.8 |
Montgomery-Asberg Depression Rating Scale ranges from 0-60. Higher score indicates more severe depression. 0-6 normal, 7-19 mild depression, 20-34 moderate depression, greater than 34 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in MADRS score (Mean) |
|---|---|
| Paroxetine | -13.6 |
| Venlafaxine Extended Release | -10.9 |
| Placebo | -6.6 |
Parkinson's Disease Questionnaire (PDQ-39) - Emotional Well-Being maximum score 24, minimum score of 0.Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PDQ-39 Emotional score (Mean) |
|---|---|
| Paroxetine | -21.4 |
| Venlafaxine Extended Release | -20.7 |
| Placebo | -10.9 |
Parkinson's Disease Questionnaire (PDQ-39) Total. Range 0-100. Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PDQ-39 score (Mean) |
|---|---|
| Paroxetine | -8.0 |
| Venlafaxine Extended Release | -8.4 |
| Placebo | -5.3 |
Pittsburgh Sleep Quality Index scores range from 0-21, with higher scores indicating severe sleep difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PQSI score (Mean) |
|---|---|
| Paroxetine | -2.1 |
| Venlafaxine Extended Release | -2.6 |
| Placebo | -1.1 |
Short Form 36 Health Survey. Range 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 mental score (Mean) |
|---|---|
| Paroxetine | 11.4 |
| Venlafaxine Extended Release | 9.5 |
| Placebo | 4.8 |
Short Form 36 Health Survey - Mental Health subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 Mental Health score (Mean) |
|---|---|
| Paroxetine | 16.7 |
| Venlafaxine Extended Release | 17.4 |
| Placebo | 9.7 |
Short Form 36 Health Survey - Emotional subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 Role score (Mean) |
|---|---|
| Paroxetine | 39.5 |
| Venlafaxine Extended Release | 26.9 |
| Placebo | 12.7 |
Short Form 36 Health Survey - Vitality subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 vitality score (Mean) |
|---|---|
| Paroxetine | 13.5 |
| Venlafaxine Extended Release | 9.1 |
| Placebo | 4.7 |
Snaith Clinical Anxiety Scale. Range 0-21. Higher scores indicate increased anxiety. Score greater than 8 indicates clinical anxiety. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in CAS score (Mean) |
|---|---|
| Paroxetine | -3.6 |
| Venlafaxine Extended Release | -3.2 |
| Placebo | -2.4 |
Unified Parkinson's Disease Rating Scale. Higher score indicates more severe Parkinson's disease symptoms. Total maximum = 176. Mental maximum = 52, Activities of Daily Living maximum = 52, Motor maximum = 72. Minimum = 0. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS score (Mean) |
|---|---|
| Paroxetine | -8.7 |
| Venlafaxine Extended Release | -7.0 |
| Placebo | -4.3 |
Unified Parkinson's Disease Rating Scale - Bulbar maximum score 24, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-Bulbar score (Mean) |
|---|---|
| Paroxetine | -1.4 |
| Venlafaxine Extended Release | -1.4 |
| Placebo | -0.5 |
Unified Parkinson's Disease Rating Scale - Motor has a maximum score of 72, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-motor score (Mean) |
|---|---|
| Paroxetine | -4.3 |
| Venlafaxine Extended Release | -2.0 |
| Placebo | -1.0 |
Unified Parkinson's Disease Rating Scale - Tremor subscale ranges from 0-23. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-tremor score (Mean) |
|---|---|
| Paroxetine | 0.4 |
| Venlafaxine Extended Release | 0.5 |
| Placebo | -0.6 |
The items mostly range from a score of 0-4 but there are some questions that range from a score of 0-2. The maximum total score that can be reported is 76 and the lowest score is 0. Higher values represent a worse outcome. Items are summed together to compute the total score. Remission is defined as two consecutive Hamilton Rating Scale for Depression, 24 items (HRSD-24) scores < 10, and HRSD-24 total score does not increase > 3 points on the second consecutive HRSD-24, or remains < 6 at the last two consecutive treatments. HRSD-24 scores are used to define remission. (NCT01881763)
Timeframe: Days required to achieve remission (on average 3-4 weeks)
| Intervention | HRSD units (Mean) |
|---|---|
| Ketamine | 7.82 |
| Methohexital | 8.60 |
3 reviews available for nortriptyline and Depression, Involutional
| Article | Year |
|---|---|
Biomarkers as predictors of treatment response to tricyclic antidepressants in major depressive disorder: A systematic review.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Biomarkers; Depressive Disorder, Major; Hum | 2022 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co | 2016 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co | 2016 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co | 2016 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co | 2016 |
Treatment of bereavement-related depression and traumatic grief.
Topics: Antidepressive Agents, Tricyclic; Bereavement; Depressive Disorder, Major; Humans; Nortriptyline; Pa | 2006 |
86 trials available for nortriptyline and Depression, Involutional
| Article | Year |
|---|---|
Influence of adjuvant nortriptyline on the efficacy of electroconvulsive therapy: A randomized controlled trial and 1-year follow-up.
Topics: Depressive Disorder, Major; Electroconvulsive Therapy; Follow-Up Studies; Humans; Nortriptyline; Rec | 2022 |
Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson's disease.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Multic | 2022 |
Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson's disease.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Multic | 2022 |
Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson's disease.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Multic | 2022 |
Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson's disease.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Humans; Multic | 2022 |
Clinical characteristics associated with relapse 2 years after electroconvulsive therapy for major depression.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Electroconvulsive Therapy; Humans; No | 2023 |
Effectiveness of Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder: A Randomized Clinical Trial.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Drug-Rel | 2023 |
Vascular risk factors in older patients with depression: outcome of electroconvulsive therapy versus medication.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Elect | 2018 |
Antidepressant drug-specific prediction of depression treatment outcomes from genetic and clinical variables.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Biomarkers; Cital | 2018 |
Genetic disposition to inflammation and response to antidepressants in major depressive disorder.
Topics: Adrenergic Uptake Inhibitors; Adult; C-Reactive Protein; Citalopram; Depressive Disorder, Major; Fem | 2018 |
Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder.
Topics: Adult; Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorder, Major; Drug Substitution; | 2019 |
Trajectories of Suicidal Ideation During 12 Weeks of Escitalopram or Nortriptyline Antidepressant Treatment Among 811 Patients With Major Depressive Disorder.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Europe; Female; Humans; Male; | 2019 |
DNA methylation in interleukin-11 predicts clinical response to antidepressants in GENDEP.
Topics: Adult; Aged; Antidepressive Agents; Citalopram; CpG Islands; Depressive Disorder, Major; DNA Methyla | 2013 |
Antidepressant treatment of melancholia in older adults.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; | 2014 |
How treatable is refractory depression?
Topics: Adult; Antidepressive Agents; Central Nervous System Stimulants; Depressive Disorder, Major; Depress | 2014 |
An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline.
Topics: Academic Medical Centers; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tr | 2014 |
Speed of remission in elderly patients with depression: electroconvulsive therapy v. medication.
Topics: Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Electroco | 2015 |
Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial).
Topics: Antidepressive Agents; Clinical Protocols; Cost-Benefit Analysis; Cytochrome P-450 CYP2D6; Depressiv | 2015 |
Relapse Prevention in Major Depressive Disorder After Successful Acute Electroconvulsive Treatment: a 6-month Double-blind Comparison of Three Fixed Dosages of Escitalopram and a Fixed Dose of Nortriptyline - Lessons from a Failed Randomised Trial of the
Topics: Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Double-Blind Method; Ele | 2015 |
Transcriptomics and the mechanisms of antidepressant efficacy.
Topics: Antidepressive Agents; Carrier Proteins; Citalopram; Cohort Studies; Depressive Disorder, Major; Eur | 2016 |
Combining clinical variables to optimize prediction of antidepressant treatment outcomes.
Topics: Age Factors; Antidepressive Agents; Area Under Curve; Body Mass Index; Citalopram; Depressive Disord | 2016 |
Absolute Measurements of Macrophage Migration Inhibitory Factor and Interleukin-1-β mRNA Levels Accurately Predict Treatment Response in Depressed Patients.
Topics: Adult; Affect; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cell-Free | 2016 |
Continuation/maintenance treatment with nortriptyline versus combined nortriptyline and ECT in late-life psychotic depression: a two-year randomized study.
Topics: Affective Disorders, Psychotic; Aged; Antidepressive Agents, Tricyclic; Combined Modality Therapy; C | 2008 |
Outcome of late-life depression after 3 years of sequential treatment.
Topics: Age of Onset; Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Double-Blind M | 2009 |
Is baseline medication resistance associated with potential for relapse after successful remission of a depressive episode with ECT? Data from the Consortium for Research on Electroconvulsive Therapy (CORE).
Topics: Adult; Aged; Antidepressive Agents; Combined Modality Therapy; Depressive Disorder, Major; Drug Resi | 2009 |
Body weight as a predictor of antidepressant efficacy in the GENDEP project.
Topics: Adult; Affect; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Appetite; | 2009 |
Sexual function in postpartum women treated for depression: results from a randomized trial of nortriptyline versus sertraline.
Topics: Adolescent; Adult; Antidepressive Agents, Tricyclic; Arousal; Depression, Postpartum; Depressive Dis | 2009 |
Early response as predictor of final remission in elderly depressed patients.
Topics: Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Dep | 2009 |
Orosomucoid influences the response to antidepressants in major depressive disorder.
Topics: Adult; Antidepressive Agents; Biomarkers; Depressive Disorder, Major; Female; Fluoxetine; Genotype; | 2010 |
Childhood neglect and abuse as predictors of antidepressant response in adult depression.
Topics: Adult; Age of Onset; Antidepressive Agents; Child; Child Abuse; Child Abuse, Sexual; Chronic Disease | 2009 |
Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects.
Topics: Adult; Aged; Antidepressive Agents; Combined Modality Therapy; Cross-Over Studies; Cyclohexanols; De | 2009 |
Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project.
Topics: Adult; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Citalopram; Depressive Disorder, Ma | 2009 |
History of suicide attempts among patients with depression in the GENDEP project.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Comor | 2010 |
Personality disorders improve in patients treated for major depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Comorbidity; Depressive Disorder, Major; Dose-Respon | 2010 |
A randomized controlled trial comparing the memory effects of continuation electroconvulsive therapy versus continuation pharmacotherapy: results from the Consortium for Research in ECT (CORE) study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Depressive Disorder, Major; D | 2010 |
Measures of temperament and character are differentially impacted on by depression severity.
Topics: Adult; Affect; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cognitive | 2010 |
Stressful life events, cognitive symptoms of depression and response to antidepressants in GENDEP.
Topics: Adult; Affect; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopra | 2010 |
Depression in Parkinson's disease: symptom improvement and residual symptoms after acute pharmacologic management.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Dysthymic Disorder; Female; | 2011 |
Variation in GNB3 predicts response and adverse reactions to antidepressants.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Europe; Female; Gene Frequency | 2011 |
Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project.
Topics: Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Female; Genome-Wide Asso | 2012 |
Health-related quality of life in a clinical trial of ECT followed by continuation pharmacotherapy: effects immediately after ECT and at 24 weeks.
Topics: Antidepressive Agents; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Drug Th | 2011 |
Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: clinical description and the role of the 5-HTTLPR.
Topics: Adrenergic Uptake Inhibitors; Adult; Alleles; Citalopram; Depressive Disorder, Major; Female; Genoty | 2011 |
Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms.
Topics: Activities of Daily Living; Adult; Affect; Antidepressive Agents, Second-Generation; Antidepressive | 2012 |
Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms.
Topics: Activities of Daily Living; Adult; Affect; Antidepressive Agents, Second-Generation; Antidepressive | 2012 |
Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms.
Topics: Activities of Daily Living; Adult; Affect; Antidepressive Agents, Second-Generation; Antidepressive | 2012 |
Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms.
Topics: Activities of Daily Living; Adult; Affect; Antidepressive Agents, Second-Generation; Antidepressive | 2012 |
Non-steroidal anti-inflammatory drugs and efficacy of antidepressants in major depressive disorder.
Topics: Adult; Age Distribution; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Tricyclic; | 2012 |
Self-report and clinician-rated measures of depression severity: can one replace the other?
Topics: Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Depressive Disorder, Major; Fem | 2012 |
Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Depressive Disorder, Major; Electrocardiography | 2002 |
Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate.
Topics: Aged; Analysis of Variance; Antidepressive Agents; Depressive Disorder, Major; Discriminant Analysis | 2002 |
Single-blind comparison of venlafaxine and nortriptyline in elderly major depression.
Topics: Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Dep | 2003 |
Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Double-Blind | 2003 |
Serum cholesterol in treatment-resistant depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Cholesterol; Depressive Disorder, Major; | 2003 |
Occurrence and course of suicidality during short-term treatment of late-life depression.
Topics: Aged; Combined Modality Therapy; Depressive Disorder; Depressive Disorder, Major; Female; Humans; Ma | 2003 |
Axis III disorders in treatment-resistant major depressive disorder.
Topics: Adult; Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder, Major; Female; Humans; Ma | 2003 |
Predictors of therapeutic effects in amitriptyline treatment--1. Plasma drug levels.
Topics: Adult; Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents, Tricyclic; Data Interpretation | 2003 |
Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline.
Topics: Adult; Age Factors; Alleles; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyc | 2003 |
Functional but not structural subgenual prefrontal cortex abnormalities in melancholia.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Tricyclic; Blood Glucose; Brain Mapping; Depress | 2004 |
No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
Topics: Adolescent; Adult; Antidepressive Agents; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Femal | 2004 |
Bipolar II disorder: personality and outcome in two clinical samples.
Topics: Adrenergic Uptake Inhibitors; Adult; Bipolar Disorder; Bulimia; Cognitive Behavioral Therapy; Depres | 2004 |
Estimating treatment effects from longitudinal clinical trial data with missing values: comparative analyses using different methods.
Topics: Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cognition Disorder | 2004 |
Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; | 2004 |
A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depressive | 2005 |
Weight changes in postpartum women with remitted depression.
Topics: Adolescent; Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depression, Postpartum; | 2005 |
Reversed diurnal variation in depression: associations with a differential antidepressant response, tryptophan: large neutral amino acid ratio and serotonin transporter polymorphisms.
Topics: Adult; Affect; Alleles; Amino Acids; Antidepressive Agents; Bipolar Disorder; Circadian Rhythm; Depr | 2005 |
Tryptophan and tyrosine availability and response to antidepressant treatment in major depression.
Topics: Adrenergic Uptake Inhibitors; Adult; Amino Acids, Neutral; Antidepressive Agents, Tricyclic; Circadi | 2005 |
Impact of cluster C personality disorders on outcomes of acute and maintenance treatment in late-life depression.
Topics: Activities of Daily Living; Acute Disease; Aged; Antidepressive Agents, Tricyclic; Cluster Analysis; | 2005 |
Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Diagnostic and Statistical | 2005 |
Genetic, developmental and personality correlates of self-mutilation in depressed patients.
Topics: Adolescent; Adult; Alleles; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricycl | 2006 |
Genetic, developmental and personality correlates of self-mutilation in depressed patients.
Topics: Adolescent; Adult; Alleles; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricycl | 2006 |
Genetic, developmental and personality correlates of self-mutilation in depressed patients.
Topics: Adolescent; Adult; Alleles; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricycl | 2006 |
Genetic, developmental and personality correlates of self-mutilation in depressed patients.
Topics: Adolescent; Adult; Alleles; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricycl | 2006 |
[Maintenance electroconvulsive therapy in elderly psychotic unipolar depression].
Topics: Aged; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Electroconvulsive Therapy; Femal | 2006 |
A comparison of effects of fluoxetine and nortriptyline on the symptoms of major depressive disorder.
Topics: Adrenergic Uptake Inhibitors; Adult; Depressive Disorder, Major; Female; Fluoxetine; Humans; Iran; M | 2006 |
A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report.
Topics: Adult; Ambulatory Care; Antidepressive Agents, Tricyclic; Bupropion; Citalopram; Cross-Over Studies; | 2006 |
Impact of prior treatment exposure on response to antidepressant treatment in late life.
Topics: Aged; Antidepressive Agents, Second-Generation; Bupropion; Combined Modality Therapy; Depressive Dis | 2006 |
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents; Depressive Disor | 2006 |
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents; Depressive Disor | 2006 |
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents; Depressive Disor | 2006 |
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents; Depressive Disor | 2006 |
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents; Depressive Disor | 2006 |
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents; Depressive Disor | 2006 |
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents; Depressive Disor | 2006 |
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents; Depressive Disor | 2006 |
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents; Depressive Disor | 2006 |
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents; Depressive Disor | 2006 |
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents; Depressive Disor | 2006 |
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents; Depressive Disor | 2006 |
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents; Depressive Disor | 2006 |
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents; Depressive Disor | 2006 |
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents; Depressive Disor | 2006 |
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents; Depressive Disor | 2006 |
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents; Depressive Disor | 2006 |
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents; Depressive Disor | 2006 |
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents; Depressive Disor | 2006 |
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents; Depressive Disor | 2006 |
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents; Depressive Disor | 2006 |
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents; Depressive Disor | 2006 |
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents; Depressive Disor | 2006 |
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents; Depressive Disor | 2006 |
Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents; Depressive Disor | 2006 |
Cerebral volume measurements and subcortical white matter lesions and short-term treatment response in late life depression.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antid | 2007 |
Venlafaxine versus nortriptyline in the treatment of elderly depressed inpatients: a randomised, double-blind, controlled trial.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; | 2007 |
Data management and design issues in an unmasked randomized trial of electroconvulsive therapy for relapse prevention of severe depression: the consortium for research in electroconvulsive therapy trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Bias; Depressive Disorder, Major; | 2007 |
Treatment of 70(+)-year-olds with recurrent major depression. Excellent short-term but brittle long-term response.
Topics: Age Factors; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Chi-Square Distribution; Com | 1999 |
Effectiveness of treatments for major depression in primary medical care practice: a post hoc analysis of outcomes for African American and white patients.
Topics: Adolescent; Adult; Antidepressive Agents; Black or African American; Combined Modality Therapy; Depr | 1999 |
The art of clinical management in pharmacologic trials with depressed elderly patients: lessons from the Pittsburgh Study of Maintenance Therapies in Late-Life Depression.
Topics: Aged; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Depressive Disorder, Major; Double | 1999 |
Which elderly depressed patients remain well on maintenance interpersonal psychotherapy alone?: report from the Pittsburgh study of maintenance therapies in late-life depression.
Topics: Age Factors; Aged; Antidepressive Agents, Tricyclic; Combined Modality Therapy; Depressive Disorder, | 1999 |
A double-blind, placebo-controlled assessment of nortriptyline's side-effects during 3-year maintenance treatment in elderly patients with recurrent major depression.
Topics: Aged; Analysis of Variance; Antidepressive Agents, Tricyclic; Body Mass Index; Body Weight; Constipa | 1999 |
Effect of nortriptyline and paroxetine on extrapyramidal signs and symptoms: A prospective double-blind study in depressed elderly patients.
Topics: Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depressive Disorde | 2000 |
Weight change in older depressed patients during acute pharmacotherapy with paroxetine and nortriptyline: a double-blind randomized trial.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Body Weight; Depressive Disorder, Major; | 2000 |
Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly.
Topics: Adrenergic Uptake Inhibitors; Aged; Depressive Disorder, Major; Double-Blind Method; Female; Follow- | 2001 |
Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; E | 2001 |
Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; E | 2001 |
Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; E | 2001 |
Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; E | 2001 |
Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; E | 2001 |
Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; E | 2001 |
Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; E | 2001 |
Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; E | 2001 |
Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; E | 2001 |
Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; E | 2001 |
Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; E | 2001 |
Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; E | 2001 |
Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; E | 2001 |
Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; E | 2001 |
Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; E | 2001 |
Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; E | 2001 |
Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; E | 2001 |
Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; E | 2001 |
Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; E | 2001 |
Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; E | 2001 |
Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; E | 2001 |
Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; E | 2001 |
Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; E | 2001 |
Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; E | 2001 |
Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; E | 2001 |
Nortriptyline in geriatric depression resistant to serotonin reuptake inhibitors: case series.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Cross-Over Studies; Depressive Disorder, | 2001 |
Adult psychosocial outcome of prepubertal major depressive disorder.
Topics: Adaptation, Psychological; Adult; Antidepressive Agents, Tricyclic; Child; Depressive Disorder, Majo | 2001 |
Dual-task performance in depressed geriatric patients.
Topics: Aged; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Double-Blind Method; Geriatric A | 2001 |
Reflections of depression in acoustic measures of the patient's speech.
Topics: Aged; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hum | 2001 |
Endogenous concentrations of DHEA and DHEA-S decrease with remission of depression in older adults.
Topics: Aged; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Depressive Disorder, Major; Dose-Respo | 2001 |
Combined pharmacotherapy and psychotherapy as maintenance treatment for late-life depression: effects on social adjustment.
Topics: Age Factors; Aged; Ambulatory Care; Antidepressive Agents, Tricyclic; Combined Modality Therapy; Dep | 2002 |
55 other studies available for nortriptyline and Depression, Involutional
| Article | Year |
|---|---|
Dimensions of temperament and character as predictors of antidepressant discontinuation, response and adverse reactions during treatment with nortriptyline and escitalopram.
Topics: Antidepressive Agents; Character; Depressive Disorder, Major; Escitalopram; Humans; Nortriptyline; P | 2023 |
Is Venlafaxine More Effective than Escitalopram and Nortriptyline in the Management of Painful Symptoms in Patients with Major Depression?
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Female; Follow-Up Studies; Hum | 2018 |
Escitalopram versus nortriptyline: how to let the clinical GENDEP data tell us what they contained.
Topics: Antidepressive Agents; Citalopram; Clinical Trials as Topic; Depressive Disorder, Major; Humans; Nor | 2013 |
Antidepressant effects of nortriptyline and escitalopram in the GENDEP study: is one better than the other?
Topics: Antidepressive Agents; Citalopram; Depressive Disorder, Major; Humans; Nortriptyline | 2013 |
[Amitriptyline versus placebo for major depression].
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Humans; Nortriptyline; | 2013 |
Norepinephrine transporter occupancy by nortriptyline in patients with depression: a positron emission tomography study with (S,S)-[¹⁸F]FMeNER-D₂.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Dose-Response Relationship, Dru | 2014 |
Transcranial magnetic stimulation as an antidepressant alternative in a patient with Brugada syndrome and recurrent syncope.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Brugada Syndrome; | 2014 |
A simple dried blood spot method for therapeutic drug monitoring of the tricyclic antidepressants amitriptyline, nortriptyline, imipramine, clomipramine, and their active metabolites using LC-MS/MS.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Biotransformation; Calibration; Chromatography, Liq | 2015 |
Response to Kunte et al.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; C-Reactive Protein; Cita | 2015 |
A new role for nortriptyline in depression associated with vascular disease?
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; C-Reactive Protein; Cita | 2015 |
More data on speed of remission with ECT in geriatric depression.
Topics: Cyclohexanols; Depressive Disorder, Major; Electroconvulsive Therapy; Female; Humans; Male; Nortript | 2015 |
Authors' reply.
Topics: Cyclohexanols; Depressive Disorder, Major; Electroconvulsive Therapy; Female; Humans; Male; Nortript | 2015 |
Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials.
Topics: Adult; Amitriptyline; Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Dose | 2015 |
Neurotrophic factors in depression in response to treatment.
Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Citalopram; Depressive Disorder, Major; Fe | 2015 |
Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Benzothiazoles; Bipolar Disorder; Bupropion; | 2016 |
Transcriptomic profiling of human hippocampal progenitor cells treated with antidepressants and its application in drug repositioning.
Topics: Antidepressive Agents; Cell Line; Citalopram; Depressive Disorder, Major; Drug Repositioning; Hippoc | 2017 |
Personalizing the care of geriatric depression.
Topics: Aged; Alzheimer Disease; Antidepressive Agents, Tricyclic; Brain; Case Management; Comorbidity; Depr | 2008 |
Identifying patients at risk of complete nonresponse in the outpatient treatment of depression.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Amitriptyline; Antidepressive Agents; Combined Modality Th | 2008 |
An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Cyclohexanol | 2009 |
Seizure threshold in a large sample: implications for stimulus dosing strategies in bilateral electroconvulsive therapy: a report from CORE.
Topics: Aged; Aging; Antidepressive Agents, Tricyclic; Calibration; Depressive Disorder, Major; Dose-Respons | 2009 |
Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Drug Resista | 2011 |
Genome-wide pharmacogenetics of antidepressant response in the GENDEP project.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; De | 2010 |
Reduced cardio-respiratory coupling after treatment with nortriptyline in contrast to S-citalopram.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Depre | 2010 |
Treatment of psychotic depression in the elderly compared with nonpsychotic depression.
Topics: Affective Disorders, Psychotic; Aged; Antidepressive Agents; Antipsychotic Agents; Cyclohexanols; De | 2010 |
Mother-infant antidepressant concentrations, maternal depression, and perinatal events.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Dose-Res | 2011 |
Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Depre | 2011 |
Non-random dropout and the relative efficacy of escitalopram and nortriptyline in treating major depressive disorder.
Topics: Antidepressive Agents; Bayes Theorem; Citalopram; Depressive Disorder, Major; Female; Follow-Up Stud | 2012 |
Pharmacologic treatment of depression in nursing home residents: a mental health services perspective.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Tricyclic; Delivery of Health | 2002 |
NORTRIPTYLINE, AN ANTIDEPRESSANT.
Topics: Alcoholism; Antidepressive Agents; Depression; Depressive Disorder; Depressive Disorder, Major; Drug | 1964 |
CLINICAL EVALUATION OF A SECONDARY AMINE, NORTRIPTYLINE.
Topics: Amines; Biomedical Research; Depressive Disorder, Major; Drug Therapy; Humans; Mental Disorders; Nor | 1964 |
CLINICAL REPORT ON PARENTERAL NORTRIPTYLINE.
Topics: Antidepressive Agents; Anxiety; Anxiety Disorders; Bipolar Disorder; Depression; Depressive Disorder | 1965 |
alpha1-acid glycoprotein in late-life depression: relationship to medical burden and genetics.
Topics: Aged; Aged, 80 and over; Alleles; Antidepressive Agents, Second-Generation; Antidepressive Agents, T | 2003 |
Trajectories of treatment response in late-life depression: psychosocial and clinical correlates.
Topics: Age Factors; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depre | 2005 |
Neuropsychological prediction of recovery in late-onset major depression.
Topics: Age of Onset; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Second-Generati | 2005 |
Placental passage of tricyclic antidepressants.
Topics: Antidepressive Agents, Tricyclic; Birth Weight; Clomipramine; Depressive Disorder, Major; Dose-Respo | 2006 |
Determining the duration of antidepressant treatment: application of signal detection methodology and the need for duration adaptive designs (DAD).
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Dose-Response Relationship, Dr | 2006 |
Augmentation with atomoxetine in treatment-resistant depression with psychotic features. A case report.
Topics: Atomoxetine Hydrochloride; Clozapine; Depressive Disorder, Major; Drug Therapy, Combination; Female; | 2006 |
Speed of improvement in sleep disturbance and anxiety compared with core mood symptoms during acute treatment of depression in old age.
Topics: Aged; Antidepressive Agents, Tricyclic; Anxiety Disorders; Cognitive Behavioral Therapy; Combined Mo | 2006 |
Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression.
Topics: Adult; Aged; Antidepressive Agents; Asian People; Depressive Disorder, Major; Female; Fluoxetine; Hu | 2006 |
Recovery from major depression in older adults receiving augmentation of antidepressant pharmacotherapy.
Topics: Age Factors; Aged; Antidepressive Agents; Bupropion; Combined Modality Therapy; Depressive Disorder, | 2007 |
What we learn about continuation treatments from the collaborative electroconvulsive therapy studies.
Topics: Antidepressive Agents; Combined Modality Therapy; Depressive Disorder, Major; Drug Therapy, Combinat | 2007 |
Monitoring nortriptyline plasma concentrations.
Topics: Adjustment Disorders; Adult; Affective Disorders, Psychotic; Bipolar Disorder; Depression; Depressiv | 1980 |
Amitriptyline, nortriptyline plasma levels and clinical response in women with affective disorders.
Topics: Adjustment Disorders; Adult; Aged; Amitriptyline; Bipolar Disorder; Depression; Depressive Disorder, | 1980 |
Elevation of nortriptyline plasma levels after cotreatment with paroxetine and thioridazine.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antipsychotic Age | 1998 |
Brain morphology and response to nortriptyline in geriatric depression.
Topics: Aged; Antidepressive Agents, Tricyclic; Brain; Depressive Disorder, Major; Female; Humans; Male; Mid | 1999 |
Dose of tricyclic antidepressants in elderly patients.
Topics: Aged; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Humans; Lofepramine; Nortriptyli | 1999 |
Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline.
Topics: Adjustment Disorders; Adolescent; Adult; Aged; Alleles; Bipolar Disorder; Cytochrome P-450 CYP2D6; D | 2000 |
Maintenance treatment for recurrent depression in late life. A four-year outcome study.
Topics: Aged; Antidepressive Agents; Combined Modality Therapy; Depressive Disorder, Major; Drug Therapy, Co | 2000 |
Age and nortriptyline concentrations in plasma ultrafiltrate.
Topics: Adult; Aged; Aged, 80 and over; Biological Availability; Depressive Disorder, Major; Dose-Response R | 2000 |
Nortriptyline toxicity secondary to interaction with bupropion sustained-release.
Topics: Adrenergic Uptake Inhibitors; Aged; Aged, 80 and over; Bupropion; Delayed-Action Preparations; Depre | 2001 |
Treatment outcome in suicidal vs. non-suicidal elderly patients.
Topics: Aged; Antidepressive Agents; Anxiety Disorders; Depressive Disorder, Major; Female; Humans; Male; No | 2001 |
Subjective health measures and acute treatment outcomes in geriatric depression.
Topics: Activities of Daily Living; Aged; Attitude to Health; Combined Modality Therapy; Depressive Disorder | 2001 |
Nortriptyline for depression and vulvodynia.
Topics: Aged; Chronic Disease; Depressive Disorder, Major; Female; Humans; Neuralgia; Nortriptyline; Treatme | 2002 |
[Antidepressive treatment with nortriptyline].
Topics: Administration, Oral; Adult; Aged; Depression; Depressive Disorder, Major; Female; Humans; Male; Mid | 1975 |
Persistent extrapyramidal oral dyskinesias following treatment with thymoleptics.
Topics: Aged; Amitriptyline; Antidepressive Agents; Depressive Disorder, Major; Facial Muscles; Female; Huma | 1970 |